GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » FCF Margin %

I-MAB (IMAB) FCF Margin % : 0.00% (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. I-MAB's Free Cash Flow for the three months ended in Sep. 2024 was $0.00 Mil. I-MAB's Revenue for the three months ended in Sep. 2024 was $0.00 Mil. Therefore, I-MAB's FCF Margin % for the quarter that ended in Sep. 2024 was 0.00%.

As of today, I-MAB's current FCF Yield % is -271.25%.

The historical rank and industry rank for I-MAB's FCF Margin % or its related term are showing as below:

IMAB' s FCF Margin % Range Over the Past 10 Years
Min: -5673.45   Med: -1139.46   Max: 518.42
Current: -5673.45


During the past 7 years, the highest FCF Margin % of I-MAB was 518.42%. The lowest was -5673.45%. And the median was -1139.46%.

IMAB's FCF Margin % is ranked worse than
90% of 1030 companies
in the Biotechnology industry
Industry Median: -144.19 vs IMAB: -5673.45


I-MAB FCF Margin % Historical Data

The historical data trend for I-MAB's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB FCF Margin % Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial -2,933.86 27.59 -1,139.46 518.42 -4,761.33

I-MAB Quarterly Data
Dec17 Jun18 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of I-MAB's FCF Margin %

For the Biotechnology subindustry, I-MAB's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's FCF Margin % distribution charts can be found below:

* The bar in red indicates where I-MAB's FCF Margin % falls into.



I-MAB FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

I-MAB's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-185.692/3.9
=-4,761.33 %

I-MAB's FCF Margin for the quarter that ended in Sep. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB FCF Margin % Related Terms

Thank you for viewing the detailed overview of I-MAB's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).